2018
DOI: 10.3389/fphar.2018.00831
|View full text |Cite
|
Sign up to set email alerts
|

Biologically Targeted Magnetic Hyperthermia: Potential and Limitations

Abstract: Hyperthermia, the mild elevation of temperature to 40–43°C, can induce cancer cell death and enhance the effects of radiotherapy and chemotherapy. However, achievement of its full potential as a clinically relevant treatment modality has been restricted by its inability to effectively and preferentially heat malignant cells. The limited spatial resolution may be circumvented by the intravenous administration of cancer-targeting magnetic nanoparticles that accumulate in the tumor, followed by the application of… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
2

Citation Types

4
334
0
5

Year Published

2019
2019
2024
2024

Publication Types

Select...
4
4
1

Relationship

0
9

Authors

Journals

citations
Cited by 407 publications
(343 citation statements)
references
References 153 publications
4
334
0
5
Order By: Relevance
“…Two approaches are most common: (a) the use of magnetic particles to improve the accumulation of drugs in a desired region via magnetic targeting (Alexiou et al, 2000;Shapiro et al, 2015) and (b) the use of magnetic fields to heat magnetic particles to directly induce hyperthermia in or ablation of diseased tissues (Hedayatnasab, Abnisa, & Daud, 2017) and/or to trigger the release of drugs from thermally sensitive carriers (Moros et al, 2019;Yoo, Jeong, Noh, Lee, & Cheon, 2013; Figure 1). As there are already a number of very comprehensive reviews on hyperthermia and thermal tissue ablation (Chang et al, 2018;Dewhirst, Lee, & Ashcraft, 2016;Périgo et al, 2015), these topics will not be discussed extensively here. Rather, we focus on approaches that have been developed for magnetic targeting of drug-loaded magnetic nanocarriers as well as magnetically induced drug release.…”
Section: Introductionmentioning
confidence: 99%
“…Two approaches are most common: (a) the use of magnetic particles to improve the accumulation of drugs in a desired region via magnetic targeting (Alexiou et al, 2000;Shapiro et al, 2015) and (b) the use of magnetic fields to heat magnetic particles to directly induce hyperthermia in or ablation of diseased tissues (Hedayatnasab, Abnisa, & Daud, 2017) and/or to trigger the release of drugs from thermally sensitive carriers (Moros et al, 2019;Yoo, Jeong, Noh, Lee, & Cheon, 2013; Figure 1). As there are already a number of very comprehensive reviews on hyperthermia and thermal tissue ablation (Chang et al, 2018;Dewhirst, Lee, & Ashcraft, 2016;Périgo et al, 2015), these topics will not be discussed extensively here. Rather, we focus on approaches that have been developed for magnetic targeting of drug-loaded magnetic nanocarriers as well as magnetically induced drug release.…”
Section: Introductionmentioning
confidence: 99%
“…This therapeutic platform is based on controlled heating of tumor tissue through the accumulation of SPION within cancer cells followed by exposure to an external alternating magnetic field (AMF). The SPION act as nano-heaters by increasing the local temperature in the range of 41-46°C [11,12], which triggers cell death mechanisms (apoptosis or/and necrosis) while altering the functionality of the protein causing high sensitivity of the cancer cells to traditional treatments (e.g. radiotherapy and chemotherapy) [13].…”
Section: Introductionmentioning
confidence: 99%
“…In contrast, an average human adult carries 3.5-4 g of iron which is an essential element for red blood cells. Accordingly, iron oxide nanoparticles, in particular magnetite (Fe 3 O 4 ) and maghemite (γ-Fe 2 O 3 ), are commonly used owing to lower toxicity and the presence of iron with different valences in their crystal structure 11 .…”
Section: Introductionmentioning
confidence: 99%